In today’s busy world, staying fit and energized can feel like a challenge. Many people are looking for natural ways t ...

The effects of sleep deprivation on cognitive function may be reversed by treatment with a compound called orexin-A, which occurs naturally in the mammalian brain. The new research was done with ...

周三，Piper Sandler维持了对Alkermes（NASDAQ:ALKS）的"增持"评级，并重申了37美元的目标价。该公司的立场受到ALKS-2680潜力的影响，这是一种目前正在开发用于治疗睡眠/觉醒障碍的orexin 2受体（OX2R）激动剂。

Satisfied, the team named them “orexin-A” and “orexin-B,” for the Greek word “orexis,” meaning appetite. The brain receptors became “orexin-1” and “orexin-2.” The team prepared ...

Japanese drugmaker Takeda has suspended dosing in phase 2 trials of its orexin agonist TAK-994, saying it had encountered a "safety signal" in the study. The future of the programme seems to be in ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

NLS Pharmaceutics (NLSP) announced that its CEO Alex Zwyer, has issued a letter to shareholders, which read in part, “Over the past several ...

Insomnia, characterized by difficulties in sleep onset and/or sleep maintenance, impacts both physical and mental health. The ...

NLS Pharmaceutics (NLSP) shared preclinical data demonstrating the potential of its dual orexin receptor agonist platform. AEX-41 and AEX-2, two first-in-class non-sulfonamide DOXAs, are designed to ...